Abstract
Over the last years, ligands for angiotensin II subtype 1 receptor (AT1R) have been developed as an alternative to the use of angiotensin-converting enzyme (ACE) inhibitors for controlling high blood pressure. Radiolabeled versions of these ligands have proven vital to the development of more potent and specific drugs for the treatment of hypertension. Imaging studies using radiolabeled AT1R ligands have also elucidated the role these receptors play in angiogenesis as well as in various disease states beyond hypertension.
Keywords: Angiotensin, AT1, carbon-11, hypertension, iodine-125, Losartan, radioligand, tritium, Angiotensin II, (AT1) Receptor, angiotensin-converting enzyme (ACE), renin-angiotensin system (RAS), ACE inhibitors, Physiological regulation, atherosclerosis, renal fibrosis, myocardial remodeling, carcinogenesis, arterial hypertension, Fibrocyte accumulation, extracellular matrix (ECM), protein kinases (MAPKs), renin-angiotensin system, ANG II PEPTIDE ANALOGS, Losartan derivatives, blood-brain barrier (BBB), Candesartan, 18F-labeled AT1 antagonist, Eprosartan, Irbesartan, Telmisartan, Valsartan, Olmesartan, SK-1080, KR31173
Current Topics in Medicinal Chemistry
Title: Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor
Volume: 10 Issue: 16
Author(s): William B. Mathews and Zsolt Szabo
Affiliation:
Keywords: Angiotensin, AT1, carbon-11, hypertension, iodine-125, Losartan, radioligand, tritium, Angiotensin II, (AT1) Receptor, angiotensin-converting enzyme (ACE), renin-angiotensin system (RAS), ACE inhibitors, Physiological regulation, atherosclerosis, renal fibrosis, myocardial remodeling, carcinogenesis, arterial hypertension, Fibrocyte accumulation, extracellular matrix (ECM), protein kinases (MAPKs), renin-angiotensin system, ANG II PEPTIDE ANALOGS, Losartan derivatives, blood-brain barrier (BBB), Candesartan, 18F-labeled AT1 antagonist, Eprosartan, Irbesartan, Telmisartan, Valsartan, Olmesartan, SK-1080, KR31173
Abstract: Over the last years, ligands for angiotensin II subtype 1 receptor (AT1R) have been developed as an alternative to the use of angiotensin-converting enzyme (ACE) inhibitors for controlling high blood pressure. Radiolabeled versions of these ligands have proven vital to the development of more potent and specific drugs for the treatment of hypertension. Imaging studies using radiolabeled AT1R ligands have also elucidated the role these receptors play in angiogenesis as well as in various disease states beyond hypertension.
Export Options
About this article
Cite this article as:
B. Mathews William and Szabo Zsolt, Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor, Current Topics in Medicinal Chemistry 2010; 10 (16) . https://dx.doi.org/10.2174/156802610793176729
DOI https://dx.doi.org/10.2174/156802610793176729 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Targeting Cerebral Vascular Injury for Intervention
Current Drug Delivery Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Current Concepts in SLE Thrombocytopenia: From Pathophysiology to Therapeutic Interventions
Current Rheumatology Reviews Functional, Genetic and Biochemical Biomarkers of Peripheral Arterial Disease
Current Medicinal Chemistry Recent Advances in Rhinovirus Therapeutics
Current Drug Targets - Infectious Disorders Development and Validation of Novel UPLC-MS/MS Method for the Analysis of Macitentan in Pharmaceutical Formulations
Current Pharmaceutical Analysis Statins Influence Long Term Restenosis and Cardiovascular Events Following Carotid Endarterectomy
Current Vascular Pharmacology High Fat Meal Increase of IL-17 is Prevented by Ingestion of Fruit Juice Drink in Healthy Overweight Subjects
Current Pharmaceutical Design Renal and Hepatic Transporter Expression in Type 2 Diabetic Rats
Drug Metabolism Letters Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Regulation of Apolipoprotein B by Natural Products and Nutraceuticals: A Comprehensive Review
Current Medicinal Chemistry Hypertension in Diabetes: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Subject Index Volume 2
Medicinal Chemistry Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Vitamin D3, D2 and Arterial Wall Properties in Coronary Artery Disease
Current Pharmaceutical Design Anti-IL-1 β Therapies
Recent Patents on DNA & Gene Sequences Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry siRNA Silencing of Gene Expression in Trabecular Meshwork: RhoA siRNA Reduces IOP in Mice
Current Molecular Medicine Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design